Manidipina Teva

Manidipine, the active ingredient in Manidipina Teva, is a calcium channel blocker presented as an oral tablet for oral use. It lowers elevated blood pressure in adults with essential hypertension.

GNH USA supplies Manidipina Teva as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Manidipine is a calcium‑channel‑blocking antihypertensive that acts on the vascular smooth‑muscle pathway to control high blood pressure.

- Hypertension: reduces systolic and diastolic blood pressure in patients with essential hypertension.

Manidipine is generally well tolerated, but several adverse reactions have been reported.

Common Side Effects: - Headache - Flushing - Peripheral edema - Dizziness - Nausea - Tachycardia

Serious or Rare Side Effects: - Severe hypotension - Myocardial infarction - Hepatic dysfunction - Allergic reactions including rash - Angioedema - Cardiac arrhythmias

Manidipine should be used with attention to several safety considerations.

- Blood pressure monitoring: check regularly to avoid excessive hypotension. - Discontinuation: avoid abrupt withdrawal in patients with severe hypertension. - Hepatic impairment: use with caution; dose adjustment may be required. - Renal impairment: monitor renal function, especially in the elderly. - Pregnancy and lactation: safety not established; avoid unless clearly needed. - Storage: Store below 25°C: keep in the original pack, protect from moisture.

Manidipine may interact with other medicines, altering its efficacy or safety.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., ketoconazole, itraconazole): may increase plasma levels. - Concomitant use with other antihypertensives: risk of additive hypotensive effect.

Moderate Interactions (Monitor Closely): - CYP3A4 inducers (e.g., rifampicin, carbamazepine): may reduce effectiveness. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): may impair renal function. - Diuretics: may enhance electrolyte disturbances. - Grapefruit juice: may increase systemic exposure. - Beta‑blockers: may require dose adjustment for heart rate control.